PDF(Sci-hub)
Abstract：
Obesity is up to 4 times higher in patients with schizophrenia than in the general population. However, the link between obesity and schizophrenia in the absence of antipsychotic use is unclear. Therefore, we aimed to examine differences in obesity measures (body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR)) in antipsychotic-naive and minimally treated (up to 2 weeks of lifetime antipsychotic exposure) patients with psychosis compared to healthy controls (HCs).
A systematic search was conducted using Ovid Medline®, PsycINFO, and Embase. Standardized mean differences (SMDs) in obesity measures between groups were calculated. Separate sensitivity analyses were performed to examine the effects of age, sex, and ethnicity; antipsychotic exposure; and schizophrenia-related psychosis on SMDs.
A total of 23 studies were included in the meta-analysis (BMI = 23, WC = 9, WHR = 5). BMI was lower (SMD = -0.19, 95% CI = -0.34 to -0.05, P = 0.009) and WHR was elevated (SMD = 0.34, 95% CI = 0.14 to 0.55, P = 0.001) in patients. These differences remained after analyses were restricted to patients matched with HCs for age, sex, and ethnicity; to antipsychotic-naive patients; and to patients with schizophrenia-related diagnoses.
Differences in BMI and WHR were observed in never and minimally treated patients with psychosis compared to HCs. Future research is warranted to understand these alterations in the context of body fat biomarkers and neuropathology of psychiatric disorders, independent of the effects of antipsychotics.
A systematic search was conducted using Ovid Medline®, PsycINFO, and Embase. Standardized mean differences (SMDs) in obesity measures between groups were calculated. Separate sensitivity analyses were performed to examine the effects of age, sex, and ethnicity; antipsychotic exposure; and schizophrenia-related psychosis on SMDs.
A total of 23 studies were included in the meta-analysis (BMI = 23, WC = 9, WHR = 5). BMI was lower (SMD = -0.19, 95% CI = -0.34 to -0.05, P = 0.009) and WHR was elevated (SMD = 0.34, 95% CI = 0.14 to 0.55, P = 0.001) in patients. These differences remained after analyses were restricted to patients matched with HCs for age, sex, and ethnicity; to antipsychotic-naive patients; and to patients with schizophrenia-related diagnoses.
Differences in BMI and WHR were observed in never and minimally treated patients with psychosis compared to HCs. Future research is warranted to understand these alterations in the context of body fat biomarkers and neuropathology of psychiatric disorders, independent of the effects of antipsychotics.
摘要：
精神分裂症患者的肥胖症比普通人群高4倍。然而,在不使用抗精神病药物的情况下,肥胖与精神分裂症之间的联系尚不清楚.因此,我们的目的是检查肥胖指标的差异(体重指数(BMI)，腰围（WC），和腰臀比（WHR））与健康对照（HCs）相比，初次服用抗精神病药和接受最低限度治疗（终生服用抗精神病药2周）的精神病患者。
使用OvidMedline®进行了系统搜索，PsycINFO,和Embase。计算了组间肥胖指标的标准化平均差异（SMD）。进行了单独的敏感性分析，以检查年龄的影响，性别,和种族；抗精神病药物暴露；和SMD上的精神分裂症相关精神病。
共有23项研究纳入荟萃分析（BMI=23，WC=9，WHR=5）。患者的BMI较低（SMD=-0.19，95％CI=-0.34至-0.05，P=0.009），WHR升高（SMD=0.34，95％CI=0.14至0.55，P=0.001）。在分析后，这些差异仍然存在于与年龄匹配的患者中，性别,和种族；初治抗精神病药的患者；以及与精神分裂症相关诊断的患者。
与HCs相比，从未接受过和最低限度治疗的精神病患者的BMI和WHR存在差异。未来的研究有必要在身体脂肪生物标志物和精神疾病的神经病理学的背景下了解这些变化，独立于抗精神病药的作用。
使用OvidMedline®进行了系统搜索，PsycINFO,和Embase。计算了组间肥胖指标的标准化平均差异（SMD）。进行了单独的敏感性分析，以检查年龄的影响，性别,和种族；抗精神病药物暴露；和SMD上的精神分裂症相关精神病。
共有23项研究纳入荟萃分析（BMI=23，WC=9，WHR=5）。患者的BMI较低（SMD=-0.19，95％CI=-0.34至-0.05，P=0.009），WHR升高（SMD=0.34，95％CI=0.14至0.55，P=0.001）。在分析后，这些差异仍然存在于与年龄匹配的患者中，性别,和种族；初治抗精神病药的患者；以及与精神分裂症相关诊断的患者。
与HCs相比，从未接受过和最低限度治疗的精神病患者的BMI和WHR存在差异。未来的研究有必要在身体脂肪生物标志物和精神疾病的神经病理学的背景下了解这些变化，独立于抗精神病药的作用。
